BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

Even if COVID-19 does disrupt operations or create a buyer’s market, Novartis will not veer from its business development strategy. The pharma was already expanding external innovation before the crisis, and has no intention of...
BioCentury | Apr 3, 2020
Product Development

April 2 Quick Takes: Horizon takes out Curzion; plus Rgenta, Merck, Novartis-Aurobindo, Kite, Teneobio and Seattle Genetics

Horizon gains sclerosis candidate via Curzion deal  Horizon Therapeutics plc (NASDAQ:HZNP) acquired privately held Curzion Pharmaceuticals Inc., giving it LPAR1 antagonist HZN-825 (CZN001). Curzion’s shareholders received $45 million up front and are eligible for milestones...
BC Extra | Jan 23, 2020
Politics & Policy

MNCs lead price cuts in China’s second round of centralized procurement

MNC originators took the deepest price cuts in the second round of China’s expanded centralized procurement program for generic and off-patent drugs. A list released Tuesday by China’s Joint Procurement Office showed that 77 winning...
BioCentury | Jan 3, 2020
Product Development

Digital learnings and modality visions: Novartis’ CEO on where R&D is headed

By C. Simone Fishburn, Editor in Chief While the most high profile event on Novartis’ digital health front last year was arguably its retreat from the Pear deal, CEO Vasant Narasimhan still counts going big...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

Ten years after the U.S. created a pathway for biosimilars--and four and a half years after the first FDA approval--a few manufacturers have demonstrated that they can overcome the technical, regulatory and commercial barriers to...
BC Extra | Nov 5, 2019
Company News

Sandoz to launch third Neulasta biosimilar

Sandoz has received FDA approval for Ziextenzo pegfilgrastim-bmez and plans to price it at a monthly wholesale acquisition cost of $3,925, a 37% discount to the WAC for Amgen neutropenia drug Neulasta. The entry of...
BC Extra | Oct 30, 2019
Company News

Oct. 30 Company Quick Takes: Clinical hold for Zolgensma; plus Biogen-Alkermes, Roche’s satralizumab, Pear-Ironwood

Partial hold for Novartis’ SMA gene therapy  FDA placed a partial clinical hold on studies of intrathecally delivered Zolgensma onasemnogene abeparvovec-xioi from Novartis AG (NYSE:NVS; SIX:NOVN) to treat spinal muscular atrophy after observing dorsal root...
BC Extra | Oct 16, 2019
Company News

Pear gearing up to sell products solo as Sandoz backs out of digital deal

While Sandoz has pulled out of its commercialization deal with Pear, the digital therapy pioneer believes it is well positioned to commercialize its flagship digital therapeutics independently. Pear Therapeutics Inc. will assume sole commercial responsibility...
BC Extra | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

Five multinational originator companies were among the winning bidders in China’s national expansion of its centralized procurement program for generic and off-patent drugs in a process that saw steep price cuts and more robust participation...
BioCentury | Sep 6, 2019
Regulation

Lackluster U.S. biosimilars market sparks radical recommendations

The lackluster U.S. biosimilars market has led to calls for a new regulatory paradigm that could slash the cost of development. Biosimilars developers and critics of the sector agree on one thing: as it has...
Items per page:
1 - 10 of 847
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

Even if COVID-19 does disrupt operations or create a buyer’s market, Novartis will not veer from its business development strategy. The pharma was already expanding external innovation before the crisis, and has no intention of...
BioCentury | Apr 3, 2020
Product Development

April 2 Quick Takes: Horizon takes out Curzion; plus Rgenta, Merck, Novartis-Aurobindo, Kite, Teneobio and Seattle Genetics

Horizon gains sclerosis candidate via Curzion deal  Horizon Therapeutics plc (NASDAQ:HZNP) acquired privately held Curzion Pharmaceuticals Inc., giving it LPAR1 antagonist HZN-825 (CZN001). Curzion’s shareholders received $45 million up front and are eligible for milestones...
BC Extra | Jan 23, 2020
Politics & Policy

MNCs lead price cuts in China’s second round of centralized procurement

MNC originators took the deepest price cuts in the second round of China’s expanded centralized procurement program for generic and off-patent drugs. A list released Tuesday by China’s Joint Procurement Office showed that 77 winning...
BioCentury | Jan 3, 2020
Product Development

Digital learnings and modality visions: Novartis’ CEO on where R&D is headed

By C. Simone Fishburn, Editor in Chief While the most high profile event on Novartis’ digital health front last year was arguably its retreat from the Pear deal, CEO Vasant Narasimhan still counts going big...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

Ten years after the U.S. created a pathway for biosimilars--and four and a half years after the first FDA approval--a few manufacturers have demonstrated that they can overcome the technical, regulatory and commercial barriers to...
BC Extra | Nov 5, 2019
Company News

Sandoz to launch third Neulasta biosimilar

Sandoz has received FDA approval for Ziextenzo pegfilgrastim-bmez and plans to price it at a monthly wholesale acquisition cost of $3,925, a 37% discount to the WAC for Amgen neutropenia drug Neulasta. The entry of...
BC Extra | Oct 30, 2019
Company News

Oct. 30 Company Quick Takes: Clinical hold for Zolgensma; plus Biogen-Alkermes, Roche’s satralizumab, Pear-Ironwood

Partial hold for Novartis’ SMA gene therapy  FDA placed a partial clinical hold on studies of intrathecally delivered Zolgensma onasemnogene abeparvovec-xioi from Novartis AG (NYSE:NVS; SIX:NOVN) to treat spinal muscular atrophy after observing dorsal root...
BC Extra | Oct 16, 2019
Company News

Pear gearing up to sell products solo as Sandoz backs out of digital deal

While Sandoz has pulled out of its commercialization deal with Pear, the digital therapy pioneer believes it is well positioned to commercialize its flagship digital therapeutics independently. Pear Therapeutics Inc. will assume sole commercial responsibility...
BC Extra | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

Five multinational originator companies were among the winning bidders in China’s national expansion of its centralized procurement program for generic and off-patent drugs in a process that saw steep price cuts and more robust participation...
BioCentury | Sep 6, 2019
Regulation

Lackluster U.S. biosimilars market sparks radical recommendations

The lackluster U.S. biosimilars market has led to calls for a new regulatory paradigm that could slash the cost of development. Biosimilars developers and critics of the sector agree on one thing: as it has...
Items per page:
1 - 10 of 847